Bayer files suit against Lupin over plans for generic pill
FRANKFURT (Reuters) - German drugmaker Bayer(BAYGn.DE) has filed a suit in the United States against Indian generic drug maker Lupin(LUPN.NS), to prevent it from selling a version of Bayer's birth-control pill Natazia there.
In the lawsuit, filed on November 28, Bayer said that Lupin is preparing to bring a copy of the Natazia pill, also called Qlaira, to U.S. markets even though Bayer's U.S. patent on the pill runs through 2026.
The complaint said Bayer would be entitled to an award of damages and treble damages for any commercial sale of the alleged copied product.
Lupin was not immediately available for comment.
Natazia is approved in the U.S. as a contraceptive and for the treatment of heavy menstrual bleeding.
Birth-control is one of the most important businesses for Bayer's pharmaceuticals arm, with contraceptive sales of 1.1 billion euros in 2011.
Bayer Pharma AG v Lupin Ltd. and Lupin Pharmaceuticals Inc. (Case 1:12-cv-01592-UNA) was filed with the U.S. District Court, District of Delaware.
(Reporting by Ludwig Burger and Marilyn Gerlach; Editing by Elaine Hardcastle)
- Tweet this
- Share this
- Digg this
- Verizon profit misses expectations, shares fall
- UPDATE 4-Zimmer to buy Biomet for $13.35 bln in latest consolidation
- UPDATE 4-Boy and girl on Korean ferry drowned with life jackets tied together
- Japan's NTT Docomo to exit Indian market - Nikkei
- UPDATE 2-U.S. proposal would ban e-cigarette sales to minors, allow advertising
India may cede top rice exporter spot under Southeast Asian price onslaught. Full Article